All the top Biotech & Pharma news in one daily newsletter.
Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣
✅ The Good News ✅
THE GOOD
Approvals & Labels
Sanofi's Infilbray (venglustat) wins FDA approval for neurological symptoms of type 3 Gaucher disease in Ph3
Small molecule, metabolic, neurological, glucosylceramide synthase inhibitor, Gaucher disease, lysosomal storage disorder - Read more
FDA approves Regeneron, Alnylam Pharmaceuticals' Livsayis (cemdisiran), first-in-class C5-directed siRNA for generalized myasthenia gravis
Small molecule, autoimmune, siRNA, generalized myasthenia gravis, complement C5 inhibitor, first-in-class - Read more
Sanofi's VaxRabeo (rabies virus inactivated strain Wistar) receives European Commission approval for rabies prophylaxis across all ages
Vaccine, infectious disease, inactivated vaccine, rabies, pre-exposure prophylaxis, post-exposure prophylaxis - Read more
PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.
Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.
✅ More Good News ✅
THE GOOD
Business Development & Partnerships
AbbVie, Disco Pharmaceuticals partner on bispecific cancer therapeutics discovery, $40M upfront, $2.5B total deal
Option-to-license, oncology, bispecific antibody, drug discovery, milestone payments - Read more
Lotte Biologics inks first commercial manufacturing deal at new $3.3B Songdo Bio Campus
Manufacturing agreement, CDMO, biologics, commercialization - Read more
Isomorphic Labs, Merck & Co. partner on AI-driven oncology small-molecule discovery with upfront payment and milestones
Research collaboration, oncology, AI/ML, small molecule, milestone payments, royalties - Read more
Novo, nference partner to study real-world impact of metabolic disease treatments using AI platform
Research collaboration, metabolic disease, AI/ML, data analytics, real-world evidence - Read more
Evotec, Bristol Myers Squibb advance protein degradation partnership with second FDA IND acceptance
Research collaboration, oncology, small molecule, AI/ML, drug discovery - Read more
Fangzhou, Baiyunshan Pharmaceutical launch AI-powered chronic disease management and digital marketing partnership
Strategic partnership, chronic disease, AI/ML, digital health, commercialization - Read more
BioLineRx sells APHEXDA royalty rights to Soleus Capital for $5.6M one-time payment
Royalty monetization, oncology, rare disease, milestone payments, small molecule - Read more
THE GOOD
Earnings & Finances
Novartis raises peak sales forecasts for Kesimpta, Scemblix, and Leqvio amid updated mid-term guidance
Monoclonal antibody, neurology, financial, revenue impact - Read more
THE GOOD
Fundraises
Boltz raises $110M Series A, expanding AI-powered molecular design for pharma
AI/ML platform, drug discovery, protein design, small molecule, platform-enabled - Read more
VitriVax raises $87M Series C to advance single-dose Lyme disease vaccine into clinic
Infectious disease, vaccine, platform technology, Lyme disease, preclinical - Read more
SELLAS Life Sciences prices $150M public offering, advancing novel cancer therapies
Oncology, clinical-stage, biopharmaceutical, novel therapies - Read more
Ansa Biotechnologies raises $71.5M oversubscribed Series C to scale guaranteed DNA synthesis platform
Synthetic biology, DNA synthesis, platform technology, AI-driven, life science tools - Read more
THE GOOD
Regulatory
AstraZeneca's (sonesitatug vedotin) Claudin 18.2-targeting ADC wins FDA priority review for advanced gastric cancer based on Ph3 data
Antibody-drug conjugate, cancer, gastric cancer, CLDN18.2, ADC - Read more
PRESENTED BY YOU?
Get the attention of 3000+ Biotech & Pharma Professionals 🤩

Gif: mostexpensivest on Giphy
Do you offer a biotech/pharma-focused product or service?
Or looking to get investor/analyst interest on your budding start-up?
Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.
Just reply to this email* or message me on LinkedIn to learn more.
*If you’re reading this on the web version, email [email protected]
❌ The Bad News ❌
THE BAD
Clinical Trials
Actinogen's Xanamem (emestedastat) fails Ph2b/3 trial in mild-to-moderate Alzheimer's disease, subgroup data explored
Small molecule, neurological, Alzheimer's disease, cortisol, 11β-HSD1 inhibitor - Read more
THE BAD
Layoffs
nChroma Bio halves workforce, halts HBV phase 1/2 trial, pivots to next-gen preclinical hepatitis program
Epigenetic silencer, infectious disease, cost reduction, strategic - Read more
THE BAD
Regulatory
FDA rebukes Johnson & Johnson for misleading bladder-sparing efficacy claims about bladder cancer drug Inlexzo
Small molecule, oncology, regulatory, operational - Read more
THE BAD
Strategic Plans
Evaxion halts infectious disease and autoimmune programs, refocuses R&D solely on oncology
Therapeutic cancer vaccine, oncology, strategic, cost reduction - Read more
You’re all caught up on the latest Pharma & Biotech News!
TLDR Biotech wants to hear from you! 📣
Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝
If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️
And lastly - connect with me on LinkedIn!

Thanks for reading! -Anis
Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here



